Olanzapine for Anorexia Nervosa

With the arguable exception of clozapine, olanzapine confers the highest risk of weight gain, obesity, and metabolic adverse effects among the second-generation, atypical neuroleptics. Yet, might that adverse effect become a therapeutic one in persons with anorexia nervosa? So wondered clinical researchers Evelyn Attia and colleagues, of Columbia University (American Journal of Psychiatry 176:6:449-456, 2019), who randomly and … Read the rest

Ketamine: antidepressant or opioid mood-elevator?

The authors of this 39-site, Janssen-sponsored, double-blind, placebo-controlled study (Vanina Popova and colleagues, American Journal of Psychiatry 176:6:428-438, 2019) submitted its findings to FDA in support of its (now successful) application for approval of intranasal S-ketamine (Esketamine) for treatment-resistant depression.

A structural and pharmacodynamic analogue of phencyclidine (PCP), S-ketamine is withal documented to act across a broad spectrum … Read the rest

More about lamotrigine-valproate interactivity (mitigated by an inducer?)

Corroborating a previously reported finding that valproate reduces the clearance of lamotrigine in adults with bipolar disorder (thereby raising its blood concentrations), and suggesting that it may do so in pediatric epileptic youth, is a study reported recently on the Web (B. Koriskova and colleagues, Basic and Clinical Pharmacology and Toxicology, published online, ahead of print, on January 25, … Read the rest

Recurrence in bipolar disorder unlikely the result of “antidepressant tolerance”

While a preponderance of studies of antidepressant-treated bipolar depression have observed equivocal long-term outcomes characterized by non-robust antidepressant response and insufficient reprise of quality of life, a recent English-language study, published in a Polish medical journal by University of Pennsylvania researcher Jay Amsterdam and Indiana University colleague L. Lorenzo-Luaces (JD. Amsterdam and L. Lorenzo-Luaces, Psychiatria Polska 52(6):957-969, 2019), attributes diminishing … Read the rest

In utero valproate exposure and ADHD


A population-based study reported by a Danish group (J. Christiansen and colleagues, JAMA Netw Open 2019 January 4; 2(1):e186606) is a recently published example that prenatal exposure to valproate may be associated with a childhood diagnosis of attention-deficit/hyperactivity disorder (ADHD).

The authors assess the statistical significance of an association between in utero exposure to valproate and subsequent diagnosis of … Read the rest